

Matthew C Riddle

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7740654/matthew-c-riddle-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

12,700
citations

43
h-index

112
g-index

134
ext. papers

15,431
ext. citations

13
avg, IF

6.46
L-index

#	Paper	IF	Citations
112	Here's to 100 Years of Insulin and Science-and More to Come!. <i>Diabetes Care</i> , 2022 , 45, 1-2	14.6	1
111	The current schemes of insulin therapy: Pro and contra. <i>Diabetes Research and Clinical Practice</i> , 2021 , 175, 108817	7.4	3
110	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 117-128	59.2	408
109	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 129-139	59.2	243
108	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1345-1351	5.6	2
107	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2021 , e14669	3.5	2
106	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021 ,	14.6	15
105	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	4
104	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2021 , 174, 1065-1072	8	6
103	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021 , 64, 2359-2366	10.3	7
102	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. <i>Cardiovascular Diabetology</i> , 2021 , 20, 194	8.7	4
101	Rediscovery of the Second β Cell Hormone: Co-replacement With Pramlintide and Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 518-521	14.6	7
100	COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. <i>Diabetes Care</i> , 2020 , 43, 1378-1381	14.6	55
99	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , 2020 , 19, 582-590	24.1	48
98	Red and Processed Meats and Health Risks: How Strong Is the Evidence?. <i>Diabetes Care</i> , 2020 , 43, 265-271	14.6	40
97	Putting Continuous Glucose Monitoring to Work for People With Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 19-21	14.6	9
96	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 106-114	18.1	42

95	Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a EditorsPExpert Forum. <i>Diabetes Care</i> , 2020 , 43, 3117-3128	14.6	23
94	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020 , 19, 199	8.7	3
93	Diabetes and COVID-19: Moving From News to Knowledge and a Glucose Hypothesis. <i>Diabetes Care</i> , 2020 , 43, 2336-2338	14.6	7
92	Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1299-1304 ²⁷	6.7	27
91	The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019 , 42, 1159-1161	14.6	7
90	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 121-130	40	917
89	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 131-138	40	228
88	A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm. <i>Diabetes Care</i> , 2019 , 42, 2161-2163	14.6	8
87	Response to Comment on Riddle et al. EditorsPExpert Forum 2018: Managing Big Data for Diabetes Research and Care. <i>Diabetes Care</i> 2019;42:1136-1146. <i>Diabetes Care</i> , 2019 , 42, e184	14.6	
86	A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 402-407	6.7	6
85	The Cost of Diabetes Care-An Elephant in the Room. <i>Diabetes Care</i> , 2018 , 41, 929-932	14.6	79
84	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a EditorsPExpert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
83	Scientific Exploration With Continuous Monitoring Systems: An Early Assessment of Arrhythmias During Hypoglycemia. <i>Diabetes Care</i> , 2018 , 41, 664-666	14.6	4
82	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 121-128	6.7	25
81	Insulin resistance and cardiovascular outcomes in the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 564-570	6.7	6
80	Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2541-2550	6.7	3
79	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 42-49	6.7	121
78	SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?. <i>Diabetes Care</i> , 2018 , 41, 2444-2447	14.6	13

77	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 1519-1529	40	771
76	Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study. <i>Diabetes Care</i> , 2018 , 41, 2346-2352	14.6	27
75	Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?. <i>Diabetes Care</i> , 2018 , 41, 1560-1562	14.6	5
74	Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target!. <i>Diabetes Care</i> , 2017 , 40, 291-300	14.6	19
73	Modern Sulfonylureas: Dangerous or Wrongly Accused?. <i>Diabetes Care</i> , 2017 , 40, 629-631	14.6	20
72	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	45
71	Human Insulin for Type 2 Diabetes: An Effective, Less-Expensive Option. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 23-24	27.4	43
70	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017 , 40, 1302-1313	14.6	7
69	Maturation of CGM and Glycemic Measurements Beyond HbA-A Turning Point in Research and Clinical Decisions. <i>Diabetes Care</i> , 2017 , 40, 1611-1613	14.6	18
68	Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). <i>Diabetes Research and Clinical Practice</i> , 2016 , 122, 133-140	7.4	19
67	Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 252-7	8.1	39
66	Increasing Patient Acceptance and Adherence Toward Insulin. <i>Postgraduate Medicine</i> , 2016 , 128 Suppl 1, 11-20	3.7	0
65	Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". <i>Diabetes Care</i> , 2016 , 39, 664-7	14.6	14
64	Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. <i>Diabetes Care</i> 2016;39:973-981. <i>Diabetes Care</i> , 2016 , 39, 973-981	14.6	1
63	Welcome reassurance about GLP-1 drugs--but they are still young and not fully grown. <i>Diabetes Care</i> , 2015 , 38, 183-5	14.6	
62	Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. <i>Diabetes Care</i> , 2015 , 38, 1558-66	14.6	28
61	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). <i>Diabetes Care</i> , 2015 , 38, 2217-25	14.6	134
60	Diabetes: Controlling glucose levels in elderly people--benefits versus risks. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 257-8	15.2	

59	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015 , 38, 2000-8	14.6	26
58	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	59.2	1393
57	Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differences. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 269-79	7.5	4
56	Comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. <i>Diabetes Care</i> 2015;38:1067-1074. <i>Diabetes Care</i> , 2015 , 38, e170-1	14.6	13
55	Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin. <i>Diabetes Care</i> , 2015 , 38, e96-7	14.6	2
54	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
53	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editorsPexpert forum. <i>Diabetes Care</i> , 2014 , 37, 2647-59	14.6	48
52	Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. <i>Diabetologia</i> , 2014 , 57, 2030-7	10.3	9
51	New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). <i>Diabetes Care</i> , 2014 , 37, 3235-43	14.6	210
50	Insulin therapy in people with type 2 diabetes: opportunities and challenges?. <i>Diabetes Care</i> , 2014 , 37, 1499-508	14.6	94
49	Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 742-9	3.2	29
48	A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2014 , 126, 135-44	3.7	10
47	New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). <i>Diabetes Care</i> , 2014 , 37, 2755-62	14.6	226
46	Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). <i>Diabetes Care</i> , 2013 , 36, 2489-96	14.6	233
45	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care EditorsPExpert Forum. <i>Diabetes Care</i> , 2013 , 36, 1779-88	14.6	114
44	Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). <i>Diabetes Care</i> , 2013 , 36, 2497-503	14.6	204
43	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. <i>European Heart Journal</i> , 2013 , 34, 3137-44	9.5	167
42	Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C. <i>Diabetes Care</i> , 2013 , 36, e181	14.6	

41	Learning about new therapies: phase 3 clinical studies--and beyond. <i>Diabetes Care</i> , 2013 , 36, 2453-5	14.6	2
40	Contributions of basal and prandial hyperglycemia to total hyperglycemia in older and younger adults with type 2 diabetes mellitus. <i>Journal of the American Geriatrics Society</i> , 2013 , 61, 535-41	5.6	25
39	Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. <i>Diabetes Care</i> , 2012 , 35, 2100-7	14.6	42
38	Reevaluating goals of insulin therapy: perspectives from large clinical trials. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012 , 41, 41-56	5.5	6
37	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
36	Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2012 , 28, 258-67	7.5	14
35	Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. <i>Diabetes Care</i> , 2012 , 35, 749-53	14.6	18
34	Glycemic control and cardiovascular mortality. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011 , 18, 104-9	4	12
33	Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. <i>Diabetes Care</i> , 2011 , 34, 2508-14	14.6	174
32	Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. <i>Diabetes Care</i> , 2010 , 33, 983-90	14.6	331
31	Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>Circulation</i> , 2010 , 122, 844-6	16.7	72
30	Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues. <i>Diabetes Care</i> , 2010 , 33, 2722-4	14.6	32
29	Reconsideration of severe hypoglycemic events in the treat-to-target trial. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11, 477-9	8.1	5
28	Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32, 1577-82	14.6	52
27	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). <i>American Heart Journal</i> , 2008 , 155, 26-32, 32.e1-6	4.9	146
26	Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. <i>Diabetes Care</i> , 2008 , 31 Suppl 2, S125-30	14.6	26
25	Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 372-4	5.6	9
24	The Transition from Oral Agents to Combination Insulin/Oral Therapy 2008 , 169-181		3

23	When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 257-64	7.5	91
22	Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>American Journal of Cardiology</i> , 2007 , 99, 34i-43i	3	125
21	Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. <i>Diabetes Care</i> , 2007 , 30, 2794-9	14.6	91
20	Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2007 , 29, 1607-19	3.5	119
19	Is initial combination therapy effective in the treatment of type 2 diabetes?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 254-5		2
18	Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. <i>Diabetes Care</i> , 2006 , 29, 435-49	14.6	87
17	The Treat-to-Target Trial and related studies. <i>Endocrine Practice</i> , 2006 , 12 Suppl 1, 71-9	3.2	23
16	ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. <i>Endocrine Practice</i> , 2006 , 12 Suppl 1, 6-12	3.2	57
15	Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. <i>Diabetes Care</i> , 2005 , 28, 254-9	14.6	362
14	Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 77-98	5.5	76
13	Making the transition from oral to insulin therapy. <i>American Journal of Medicine</i> , 2005 , 118 Suppl 5A, 14S-20S	2.4	21
12	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. <i>Diabetes Care</i> , 2005 , 28, 1083-91	14.6	1034
11	Timely initiation of basal insulin. <i>American Journal of Medicine</i> , 2004 , 116 Suppl 3A, 3S-9S	2.4	50
10	The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. <i>Diabetes Care</i> , 2003 , 26, 3080-6	14.6	1267
9	The underuse of insulin therapy in North America. <i>Diabetes/Metabolism Research and Reviews</i> , 2002 , 18 Suppl 3, S42-9	7.5	75
8	Pramlintide: an agent for glycemic control plus weight control?. <i>Diabetes Technology and Therapeutics</i> , 2002 , 4, 63-5	8.1	3
7	Measuring fructosamine at home. <i>Diabetes Technology and Therapeutics</i> , 2000 , 2, 239-40	8.1	3
6	Combining sulfonylureas and other oral agents. <i>American Journal of Medicine</i> , 2000 , 108 Suppl 6a, 15S-22S		91

- 5 Insulin Glargine. *Drugs*, **2000**, 59, 261-262 12.1
- 4 Standardization of hemoglobin A1c values. *Annals of Internal Medicine*, **2000**, 132, 676 8
- 3 Tactics for type II diabetes. *Endocrinology and Metabolism Clinics of North America*, **1997**, 26, 659-77 5.5 23
- 2 Strategies for non-insulin-dependent diabetes mellitus. *Hospital Practice (1995)*, **1993**, 28, 14, 17-8, 20 2.2
- 1 Evening insulin strategy. *Diabetes Care*, **1990**, 13, 676-86 14.6 88